Hui Jing Yu, PhD, joined Vaxxinity as a medical director leading clinical programs focused on neurodegenerative disorders associated with misfolded proteins. She has successfully led the completion of early phase clinical trials with an anti-amyloid vaccine and the first clinical trial of an alpha-synuclein vaccine in humans. Dr. Yu has more than ten years of experience in neuroscience research with involvement in a wide variety of neurological indications. She previously worked at United Neuroscience and at Axovant Sciences, where she oversaw the design, implementation and execution of clinical trials in Lewy body dementia. She spent five years at Bioclinica as a Medical Imaging and Biomarker Scientist. Dr. Yu received academic degrees from the Stony Brook University and performed significant academic research in radiology, neurology and neurophysiology. Her neuroscience foundations and aptitude for applying imaging and biomarkers to early-stage neurology clinical trials is highly valued to the development of Vaxxinity’s pipeline.